Navigation Links
Adis Journals Make Impressive Impact Factor Gains
Date:7/18/2011

YARDLEY, Pa., July 18, 2011 /PRNewswire/ -- Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to pharmaceutical and healthcare professionals, today announced strong impact factor (IF) gains for its Adis line of drug therapy and patient management journals.  11 of the 13 Adis journals that carried IFs in 2009 bettered their performance in 2010 according to the annual Journal Citation Reports® published in June.The most impressive gains over 2009 were made by PharmacoEconomics (IF 3.44) – up 34 percent to become the leading Health Outcomes Research journal, and Sports Medicine (IF 5.072) - up 63 percent, also becoming the highest ranking title in its field.

Drugs in R&D (IF 1.707), re-launched in 2010 as Adis' first fully open access MEDLINE-indexed journal gained 26 percent. Other standout performers include CNS Drugs (IF 4.497) - up 16 percent and Biodrugs (IF 4.192) – up 20 percent.  

"The price of Adis journals was significantly restructured at the end of 2009 providing affordable access for a wider group of customers," said Iain Spray, Adis Product Manager, Wolters Kluwer Pharma Solutions.  "These IF gains are partly the result of that increased access, and the continued determination of our editors, editorial boards and publishing team to strive for the highest level of quality."

An impact factor quantifies the relative influence of a scholarly journal in its scientific field.  It is a measure of the frequency with which the average article in a journal has been cited in a given year.

For more than 40 years, medical and scientific researchers have turned to Adis for its high quality, peer-reviewed content. Adis journals, covering the evidence-based pharmacology spectrum from clinical pharmacology to drug development and drug safety, to pharmacoeconomics, medical biotechnology and disease management, are available on AdisOnline (http://adisonline.com).  

For more information, visit the company's website at www.wolterskluwerpharma.com.

About Wolters Kluwer Pharma SolutionsWolters Kluwer Pharma Solutions, Inc. (Phoenix, AZ and Yardley, PA) is a leading provider of information and analytics to the pharmaceutical, biotech, and medical device industries. The company's brands include Adis, Source® and Lippincott Williams & Wilkins. A provider of business intelligence and services, Adis publishes 19 peer-reviewed drug research journals and 2 newsletters and offers the most respected drug and clinical trials databases in the pharma industry. Lippincott Williams & Wilkins (LWW) is a leading international healthcare publisher with nearly 300 periodicals and 1,500 books in more than 100 disciplines. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. For more information, visit www.wolterskluwerpharma.com.

The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer's leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer has 2010 annual revenues of euro 3.6 billion ($4.7 billion), employs approximately 18,200 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.Contact:

Tom KivettKivett & Company Communications+1 212 727-2935tkivett@kivettandco.com
'/>"/>

SOURCE Wolters Kluwer Pharma Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adis Journals Embrace Open Access
2. Reprints Desk Bolsters Ultra-Rapid Document Delivery Service Through New Electronic Sourcing Agreement with the American Medical Association, Publisher of JAMA & Archives Journals
3. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
4. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
7. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
8. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
9. ImpactRx Measures How Patient Brand Requests Drive Physician Treatment Decisions
10. Update on IMPACT Study Results
11. Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2017)... RALEIGH, N.C. , July 19, 2017  Mako ... Veteran Affairs, and the Military Family Assistance Fund (MFA) ... Louisiana to visit with their families one ... the funding to coordinate the travel and logistics needed ... supporting our deployed soldiers and their families. We just ...
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful carpal tunnel ... syndrome affects more than 8 million people a year. Women suffer ... common methods of treating CTS are painful surgery, the use of ... ... is a clear patch worn on the palm of the hand. ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen Miller ... to communities in the greater Birmingham area, is joining the Chris Hammond Youth ... people in the region. , The Chris Hammond Youth Foundation maintains athletic facilities ...
(Date:7/21/2017)... ... ... Fresh Wave® IAQ today announced the launch of its innovative Smoke ... the APPA 2017 Annual Conference and Exhibition in Booth #414. , Specifically ... use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric Liquid is ...
(Date:7/21/2017)... , ... July 21, 2017 , ... Hospital M&A activity ... HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the second quarter, ... and up 15% from the 20 announced deals in the year-ago second quarter. Only ...
(Date:7/21/2017)... ... ... The Margarian Law Firm has filed a class action lawsuit against ... no ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ale products. In ... Ginger Ale claims on its bottle that it is made from real ginger. , ...
(Date:7/21/2017)... Basking Ridge, NJ (PRWEB) , ... July 21, ... ... Hills (VNA) has received a $5,000 grant from the C. R. ... Adult Day Center at Somerset Hills , a service available through the ...
Breaking Medicine News(10 mins):